Literature DB >> 29175241

Clinical management of polycystic liver disease.

René M M van Aerts1, Liyanne F M van de Laarschot1, Jesus M Banales2, Joost P H Drenth3.   

Abstract

A 41-year old female underwent a computed tomography (CT) scan in 2010 because of symptoms suggestive of appendicitis. Incidentally, multiple liver lesions characterised as cysts were detected. The presence of small to medium sized liver cysts (diameter between <1 cm and 4 cm) in all liver segments (>100 cysts) and absence of kidney cysts in the context of normal renal function led to the clinical diagnosis of autosomal dominant polycystic liver disease (ADPLD). Five years later she was referred to the outpatient clinic with increased abdominal girth, pain in the right upper abdomen and right flank, and early satiety. She had difficulties bending over and could neither cut her toenails nor tie her shoe laces. In her early twenties she had used oral contraception for five years. She has been pregnant twice. Clinical examination showed an enlarged liver reaching into the right pelvic region and crossing the midline of the abdomen. Laboratory testing demonstrated increased gamma-glutamyl transferase (80 IU/L, normal <40 IU/L) and alkaline phosphatase (148 IU/L, normal <100 IU/L) levels. Bilirubin, albumin and coagulation times were within the normal range. A new CT scan in 2015 was compatible with an increased number and size of liver cysts. The diameter of cysts varied between <1 cm and 6 cm (anatomic distribution shown [Fig. 2B]). There were no signs of hepatic venous outflow obstruction, portal hypertension or compression on the biliary tract. Height-adjusted total liver volume (htTLV) increased from 2,667 ml/m in 2012 to 4,047 ml/m in 2015 (height 172 cm). The case we present here is not uncommon, and prompts several relevant questions.
Copyright © 2017 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Clinical management; Complications; Liver cysts; Liver volume; PLD-Q; POLCA; Polycystic liver disease; Quality of life; Treatment

Mesh:

Year:  2017        PMID: 29175241     DOI: 10.1016/j.jhep.2017.11.024

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  38 in total

Review 1.  Pathobiology of inherited biliary diseases: a roadmap to understand acquired liver diseases.

Authors:  Luca Fabris; Romina Fiorotto; Carlo Spirli; Massimiliano Cadamuro; Valeria Mariotti; Maria J Perugorria; Jesus M Banales; Mario Strazzabosco
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2019-08       Impact factor: 46.802

2.  Update on Polycystic Liver Disease.

Authors:  Stuart C Gordon
Journal:  Gastroenterol Hepatol (N Y)       Date:  2020-01

Review 3.  Jaundice in Polycystic Liver Disease: More Than Meets the Eye.

Authors:  Danielle Brandman
Journal:  Clin Liver Dis (Hoboken)       Date:  2021-04-13

Review 4.  A Practical Approach to Polycystic Liver Disease.

Authors:  Armani Patel; Arlene B Chapman; Adam E Mikolajczyk
Journal:  Clin Liver Dis (Hoboken)       Date:  2019-12-20

5.  Symptom relief and quality of life after combined partial hepatectomy and cyst fenestration in highly symptomatic polycystic liver disease.

Authors:  Lucas H P Bernts; Myrte K Neijenhuis; Marie E Edwards; Jeff A Sloan; Jenna Fischer; Rory L Smoot; David M Nagorney; Joost P H Drenth; Marie C Hogan
Journal:  Surgery       Date:  2020-05-08       Impact factor: 3.982

6.  Automatic Measurement of Kidney and Liver Volumes from MR Images of Patients Affected by Autosomal Dominant Polycystic Kidney Disease.

Authors:  Maatje D A van Gastel; Marie E Edwards; Vicente E Torres; Bradley J Erickson; Ron T Gansevoort; Timothy L Kline
Journal:  J Am Soc Nephrol       Date:  2019-07-03       Impact factor: 10.121

7.  Proteostasis disturbances and endoplasmic reticulum stress contribute to polycystic liver disease: New therapeutic targets.

Authors:  Alvaro Santos-Laso; Laura Izquierdo-Sanchez; Pedro M Rodrigues; Bing Q Huang; Mikel Azkargorta; Ainhoa Lapitz; Patricia Munoz-Garrido; Ander Arbelaiz; Francisco J Caballero-Camino; Maite G Fernández-Barrena; Raul Jimenez-Agüero; Josepmaria Argemi; Tomas Aragon; Felix Elortza; Marco Marzioni; Joost P H Drenth; Nicholas F LaRusso; Luis Bujanda; Maria J Perugorria; Jesus M Banales
Journal:  Liver Int       Date:  2020-05-06       Impact factor: 5.828

8.  IFT-A deficiency in juvenile mice impairs biliary development and exacerbates ADPKD liver disease.

Authors:  Wei Wang; Tana S Pottorf; Henry H Wang; Ruochen Dong; Matthew A Kavanaugh; Joseph T Cornelius; Katie L Dennis; Udayan Apte; Michele T Pritchard; Madhulika Sharma; Pamela V Tran
Journal:  J Pathol       Date:  2021-05-21       Impact factor: 7.996

9.  Targeting UBC9-mediated protein hyper-SUMOylation in cystic cholangiocytes halts polycystic liver disease in experimental models.

Authors:  Pui Y Lee-Law; Paula Olaizola; Francisco J Caballero-Camino; Laura Izquierdo-Sanchez; Pedro M Rodrigues; Alvaro Santos-Laso; Mikel Azkargorta; Felix Elortza; Maria L Martinez-Chantar; Maria J Perugorria; Patricia Aspichueta; Marco Marzioni; Nicholas F LaRusso; Luis Bujanda; Joost P H Drenth; Jesus M Banales
Journal:  J Hepatol       Date:  2020-09-17       Impact factor: 25.083

Review 10.  New insights on the role of vascular endothelial growth factor in biliary pathophysiology.

Authors:  Valeria Mariotti; Romina Fiorotto; Massimiliano Cadamuro; Luca Fabris; Mario Strazzabosco
Journal:  JHEP Rep       Date:  2021-02-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.